Second-generation cephalosporin (oral axetil prodrug) indicated for pharyngitis/tonsillitis, acute otitis media, sinusitis, acute exacerbations of chronic bronchitis, uncomplicated urinary tract infections and skin/soft-tissue infections.
Also known as: Cefuroxima, Zinnat
DailyMed approved label (Cefuroxime Axetil Tablet; setID 76cec54f-d167-4298-951b-5411a3c47f4a).
DailyMed approved label (Cefuroxime Axetil Tablet; setID 76cec54f-d167-4298-951b-5411a3c47f4a).
No documented drug–drug interactions for this medicine.
Alcohol may worsen the gastrointestinal effects of cefuroxime; limit intake.
Limit alcohol intake during treatment.
DailyMed/FDA (NIH/NLM) — approved Cefuroxime Axetil label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76cec54f-d167-4298-951b-5411a3c47f4a
Cefuroxime axetil should be taken after meals: food improves its absorption and reduces gastrointestinal discomfort.
Take immediately after a meal.
DailyMed/FDA (NIH/NLM) — approved Cefuroxime Axetil label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76cec54f-d167-4298-951b-5411a3c47f4a
Cefuroxime is renally excreted; in renal impairment the dose must be adjusted.
Adjust the dose to renal function.
DailyMed/FDA (NIH/NLM) — approved Cefuroxime Axetil label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76cec54f-d167-4298-951b-5411a3c47f4a
Cefuroxime is a cephalosporin; it is contraindicated in prior cephalosporin allergy and requires caution in severe penicillin allergy.
Contraindicated in cephalosporin allergy; caution in severe penicillin allergy.
DailyMed/FDA (NIH/NLM) — approved Cefuroxime Axetil label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76cec54f-d167-4298-951b-5411a3c47f4a
Cephalosporins, including cefuroxime, are generally safe in pregnancy when indicated.
May be used in pregnancy when indicated, at the usual doses.
Excreted into breast milk in small amounts; compatible with breastfeeding.
No specific additional contraception.
DailyMed/FDA (NIH/NLM) — approved Cefuroxime Axetil label: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76cec54f-d167-4298-951b-5411a3c47f4a
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Second-generation cephalosporin: time above the MIC is the predictive efficacy parameter. Extended Gram-negative spectrum, including beta-lactamase-producing strains of H. influenzae and M. catarrhalis.
Inhibition of cell-wall synthesis by binding to PBPs; axetil (oral prodrug) is hydrolyzed by intestinal mucosa and blood esterases to active cefuroxime.
Oral absorption is enhanced with food (bioavailability from 37% fasting to 52% fed); plasma peaks at 2–3 h; elimination half-life ~1.2 h.
Predominantly renal excretion unchanged; elimination half-life prolongs with severity of renal impairment (~3.4 h in moderate/severe impairment).
Mean elimination half-life ~1.2–1.3 h (125–1000 mg tablets).
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
